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Wip1 phosphatase plays an important role in cancer by inactivating p53 and INK4a/ARF pathways. In this
issue of Cancer Cell, Filipponi and colleagues further connect the oncogenic role of Wip1 with heterochro-
matin dynamics, transposable element expression, and a mutation-prone environment that may enhance
heterogeneity and ultimately contribute to tumor evolution.The protein phosphatase Mg/Mn depen-
dent 1D (PPM1D), also known as wild-
type p53-induced phosphatase 1 (Wip1),
plays an important role in cancer by
promoting the termination of the DNA
damage response pathway and cell cycle
progression. In concordance with this
oncogenic activity, Wip1/PPM1D is often
overexpressed in breast tumors and other
types of human tumors. In this issue of
Cancer Cell, Filipponi et al. (2013) reveal
a new role for Wip1: connecting hetero-
chromatin dynamics, transposable ele-
ment (TE) expression, and, ultimately,
genomic fluidity in cancer.
TE-derived sequences comprise more
than half of the human genome, and the
activity of currently active TEs continues
to generate genomic fluidity in our
genome (Beck et al., 2011). In the human
genome, long interspersed element
class-1 (LINE-1 or L1) is the only active
autonomous TE. LINE-1s comprise 20%
of the human genome, although only
80–100 L1s remain retrotranspositionally
active (Beck et al., 2011). Additionally,
two nonautonomous retrotransposons,
Alu and SVA (comprising 10% and <1%
of our genome, respectively), canmediate
their mobilization using the LINE-1-
encoded enzymatic machinery (reviewed
in Beck et al., 2011). These three non-
LTR retrotransposons move in our
genome by a ‘‘copy and paste’’ mecha-
nism using an intermediate RNA. Active
LINE-1 s are 6-kb-long elements contain-
ing a 50 untranslated region (UTR) with
internal promoter activity, two ORFs
encoding protein products required for
retrotransposition, and end in a short30UTR with a poly(A) tail. As ‘‘mobile’’
DNA, new LINE-1 insertions can be muta-
genic by amyriad of mechanisms, leading
to gene inactivation and/or gene deregu-
lation processes. Thus, the host has
evolved multiple mechanisms aimed to
reduce the mutagenic load generated by
LINE-1 s. Controlling LINE-1 transcription
is the most effective manner to control TE
activity, because it will abolish mobiliza-
tion of not only LINE-1, but also Alu and
SVA. Notably, the 50UTR of mammalian
LINE-1 s contains a canonical CpG island
that serves to regulate its expression by
DNA-methylation (Yoder et al., 1997).
Somatic tissues and germ cells efficiently
silence LINE-1 expression by DNA
methylation, avoiding accumulation of
LINE-1 insertions. However, the LINE-1
promoter is hypomethylated during
embryogenesis (leading to the accumula-
tion of new LINE-1 s that will be trans-
mitted to newborns) and in several types
of tumors. Indeed, recent studies have
demonstrated that selected TEs are
active in lung, colorectal, prostate,
ovarian, myeloma, glioblastoma, and
hepatic tumors (Iskow et al., 2010; Lee
et al., 2012; Shukla et al., 2013; Solyom
et al., 2012). These data indicate that, on
top of other forms of cellular stress, can-
cer cells can be impacted by potentially
mutagenic new TE insertions.
DNA damage response (DDR) is often
deregulated in cancer, leading to genomic
instability. Wip1 is a DDR regulator in the
germline. Additionally, the Wip1/PPM1D
gene is often amplified in human cancers,
whereas genomic depletion in mouse
models suggests that Wip1 may act as aCancer Cell 24tumor regulator. Interestingly, Filipponi
et al. (2013) now demonstrate that Wip1
maintains the epigenetic homeostasis
of TEs associated to heterochromatin
(including active LINE-1s), providing a
mechanistic link between DNA-methyl-
ation and LINE-1 expression in the germ-
line and in cancer.
In a mouse knockout (KO) model for
Wip1, Filipponi et al. (2013) confirmed
that Wip1 deletion results in attenuated
spermatogenesis. Surprisingly, Wip1
deletion also results in increases of het-
erochromatin centers in germ cells and a
concomitant reduction in the expression
levels of LINE-1 and intracisternal A-type
particle endogenous retrovirus mRNAs.
Whether fewer TE insertions accumulate
in these mice remains to be determined.
Importantly, Wip1 might be the first posi-
tive regulator of LINE-1 expression and
retrotransposition. Further experiments
revealed that depletion of Wip1 in human
cancer cell lines results in increased levels
of repressive histone marks on LINE-1
promoters and reduced levels of ex-
pression. Furthermore, depletion of Wip1
in human cancer and mouse germ
cells led to reduced DNA-methylation
levels in LINE-1 (and endogenous retrovi-
ruses) promoters. Consistently, increased
LINE-1 mRNA expression levels (and
reciprocal changes in histone marks and
DNA methylation) were detected upon
Wip1 overexpression in cancer cells. Alto-
gether, these data indicate that Wip1
participates in controlling the homeosta-
sis of TE epigenetic regulation.
Consistent with previous reports, Fili-
pponi et al. (2013) confirmed that the, October 14, 2013 ª2013 Elsevier Inc. 405
Figure 1. Wip1 Overexpression Is often Observed in Breast Cancer, Suppressing ATM
Signaling
Suppression of ATM signaling avoids formation of a BRCA1-HP1-DNMT3B complex and subsequent DNA
methylation. DNA hypomethylation on LINE-1s upon overexpression of Wip1 results in increased
L1-mRNA expression and likely subsequent retrotransposition. Increased LINE-1 retrotransposition is a
source of genomic fluidity and can potentially create mutagenic insertions. Also depicted in the diagram
is the direct regulation of LINE-1 retrotransposition by ATM. Additionally, Wip1/AID/APOBEC overexpres-
sion can act as a source of somatic mutations in cancer (C-to-T), mostly on non-methylated cytosines. AID
performs the conversion of cytosine to uracil, which can be repaired by base excision repair (BER). How-
ever, BER is negatively regulated byWip1, leading to mutation accumulation. Thus, there are two sources
of genomic fluidity—AID-unrepaired substitutions and potential LINE-1 insertions—that can impact tumor
evolution.
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constitutively activated upon Wip1/
PPM1D deletion, resulting in the activa-
tion of the downstream effector BRCA1.
Additional data demonstrates that
BRCA1 interacts with the DNA methyl-
transferase DNMT3B through HP1 bind-
ing, forming a BRCA1-HP1-DNMT3B
complex that modulates the LINE-1 pro-
moter DNA-methylation (Figure 1). These
data strongly suggest that BRCA-1 is
involved in DNA-methylation in an ATM-
dependent manner. In the germline,
depletion of the DNMT3L results in
global reduction of retrotransposon
DNA methylation and significant in-
creases in retrotransposon mRNA levels
(Bourc’his and Bestor, 2004). It has
been suggested that meiotic failure of
DNMT3L-KO mice is a result of retro-
transposons overexpression and deregu-
lated retrotransposition. Thus, it is likely
that a balance between BRCA1-HP1-
DNMT3B and DNMT3L complexes on
TE DNA methylation allows normal
meiosis to succeed in germ cells, regu-
lating a physiological level of TE expres-
sion and retrotransposition.406 Cancer Cell 24, October 14, 2013 ª2013Furthermore, elegant genetic experi-
ments demonstrate that defects in sper-
matogenesis in Wip1-KO mice can be
rescued by the deletion of a single ATM
allele, suggesting that ATM is required
to establish DNA methylation upon
Wip1/PPM1D depletion. Interestingly,
previous studies have demonstrated that
ATM depletion results in increased levels
of engineered LINE-1 retrotransposition
in a mouse model and human cell
lines (primary and transformed) (Coufal
et al., 2011). These data reveal that
there is complex regulation of LINE-1
expression and retrotransposition in-
volving ATM-signaling and Wip1 path-
ways (Figure 1).
In human cancer cell lines, Wip1 over-
expression correlate with increased levels
of LINE-1 mRNAs, including mRNA
derived from potentially active elements.
Filipponi et al. (2013) further examined
whether alterations in Wip1/PPM1D
expression, heterochromatin dynamics,
and DNA methylation correlate with
genomic fluidity observed in breast can-
cer samples. Indeed, cytidine deami-
nases are involved in generating pointElsevier Inc.mutations in an epigenetically dependent
manner. Activation-induced cytidine
deaminase (AID) removes the amino
group from a cytosine base and turns it
into uracil (which is recognized as a
thymine). This deamination may lead to
mutation if not corrected by DNA repair.
Notably, AID is enriched in TE sequences
in a Wip1-dependent manner. Consistent
with this, breast cancer samples with an
increased copy number of Wip1/PPM1D
contain more C-to-T mutations, likely
mediated by differential AID binding in a
Wip1-dependent manner (Figure 1). Addi-
tionally, the accumulation of the AID
mutations is also favored, because Wip1
overexpression inhibits base excision
repair. Interestingly, a strong correlation
was observed between the expression
level of the APOBEC3B cytidine deami-
nase, AID, Wip1, and overall C-to-T sub-
stitution load. APOBEC3B has been
recently shown to generate genomic edit-
ing in cancer genomes (Burns et al.,
2013), consistent with the findings
reported by Filipponi et al. (2013). Intrigu-
ingly, several APOBEC cytidine deami-
nases are known to efficiently inhibit
LINE-1-engineered and Alu-engineered
retrotransposition by an elusive mecha-
nism (Beck et al., 2011). Thus, it is
tempting to speculate that a balance
between AID, APOBECs, and Wip1 might
regulate the load of somatic retrotranspo-
sition observed in different human can-
cers. Future experiments are required to
determine to what extent Wip1 modulate
the somatic load of LINE-1 retrotransposi-
tion in cancer.
In conclusion, DNA hypomethylation
in Wip1/PPM1D-overexpressing tumors
may promote genomic fluidity by the
accumulation of mutations induced by
TE transposition and AID deamination
(Figure 1). These data also reveal how
the regulation and the impact of retro-
transposition in cancer development
might be more complex than previously
anticipated.
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Tumor-bone cell interactions are critical for the development of metastasis-related osteolytic bone destruc-
tion. In this issue ofCancer Cell, Ell and colleagues show how a discretemiRNA network regulates osteoclas-
togenesis during breast cancer bone metastasis. A signature of upregulated miRNAs may have diagnostic
and therapeutic implications for bone metastases.Advanced breast cancer commonly
metastasizes to bone, where it causes os-
teolytic bone destruction and associated
bone pain and fracture, hypercalcemia,
and paralysis due to spinal cord compres-
sion. In thebonemicroenvironment, tumor
cells hijack the bone remodeling process,
normally orchestrated by osteoclasts, os-
teoblasts, andosteocytes, towreak havoc
and weaken the bone. Osteoclast differ-
entiation and bone resorption is depen-
dent on macrophage colony-stimulating
factor and receptor activator of NF-kB
ligand (RANKL) (Boyle et al., 2003). Once
in the bone, breast cancer cells release
factors that send osteoclasts into over-
drive by recruiting preosteoclasts and
inducing their differentiation. Osteoclastic
bone resorption releases growth factors
stored in the bone, such as transforming
growth factor b (TGF-b), which in turn
drives tumor cell production of factors
that further increase osteoclast activity
(Weilbaecher et al., 2011). This feed-forward vicious cycle creates a fertile
microenvironment for tumor growth in
bone to drive the devastating effects of
bone destruction and render the tumor
incurable.
Therapy for patients with bone metas-
tases attacks the tumor cells as well
as the bone microenvironment. Antire-
sorptive therapy, bisphosphonates (zole-
dronic acid), and the RANKL antibody
(denosumab) are standard-of-care to
target osteoclast hyperactivity. These
drugs effectively reduce skeletal-related
events due to bone metastases but do
not cure disease. Further, it is difficult to
predict whowill develop bonemetastases
due to lack of broadly applicable bio-
markers to better guide long term preven-
tive therapy.
In this issue of Cancer Cell, Ell et al.
(2013) propose a single approach to treat
and predict bone metastases based
on microRNA (miRNA). Specifically, they
identify a miRNA signature induced byhighly metastatic tumor cells that stimu-
lates differentiation of osteoclasts and
recruits preosteoclasts to the site of the
tumor-bone interface (Figure 1). miRNAs
repress gene expression through comple-
mentary binding to the ‘‘seed sequence’’
of mRNAs (Bartel, 2009) and are impor-
tant for osteoclastogenesis (Mizoguchi
et al., 2010; Sugatani and Hruska, 2007;
Zhang et al., 2012). Here, the authors
demonstrate how breast cancer cell inva-
sion in the bone co-opts this normal pro-
cess to hyperactivate osteoclasts and
prime the bone for osteolytic destruction.
This represents significant insight into our
understanding of the organ-specific func-
tion and pathological activity of miRNAs,
which could lead to improvements in
diagnosis, treatment, and prevention of
bone metastases and elucidates a unique
aspect of the bone microenvironment to
support tumor growth in bone.
To identify miRNAs modulated during
osteoclastogenesis, the authors used, October 14, 2013 ª2013 Elsevier Inc. 407
